Defymed enters partnership with Semma Therapeutics
Strasbourg, 12 December 2016 - Defymed, a Strasbourg biotech company specialising in the development of bio-artificial organs, announces a strategic collaboration with Semma Therapeutics, an American biotechnology company specialising in the development of cell therapies for the treatment of diabetes, with the goal of developing of an innovative solution for treating type-1 diabetes.
The collaboration is aimed at pre-clinical validation of the MAILPAN® bio-artificial pancreas, a device developed by Defymed, in combination with stem-cell derived differentiated insulin-secreting cells developed by Semma Therapeutics. The combination will be evaluated for effectiveness and safety, at first in vitro and then in an animal model.
MAILPAN® is a medical device in the form of a pouch made of bio-compatible polymer comprising semi-permeable membranes that allow glucose, nutriments and oxygen to pass through and hence to reach the pancreatic cells contained in the device, delivering the insulin required to regulate the patient’s blood-sugar level. The membranes are impermeable to the immune system and its antibodies, thereby protecting the patient from rejection of the implanted cells.
If successful, the collaboration could be an important step in the fight against the global epidemic of diabetes. Diabetes affects more than 420 million people globally, accounting for around $700B in healthcase spending. Type 1 diabetes alone accounts for $14.9 billion in healthcare costs in the U.S., with 1.25M patients on insulin therapy for the disease. In France, it is estimated that 300 000 people have type-1 diabetes, and 2 000 new cases are diagnosed each year.
This therapy would potentially offer the patient an unlimited source of insulin-secreting cells, unlike pancreatic islets which are limited by their availibility. Additionally, the device should obviate the need for immuno-suppression treatment, as its membranes as expected to protect the encapsulated cells from any risk of rejection. The patient would no longer have to think about multiple insulin injections each day, as the MAILPAN® combined with Semma’s cells should deliver the right amount of insulin. Defymed’s autonomous and long-lasting medical device thereby is hoped to substantially reduce the complications connected with diabetes.
“Semma Therapeutics’ expertise could represent a major new source for cells usable in our medical device,” said Dr Séverine Sigrist, Founding President of Defymed. “It is vital in Defymed’s strategy to validate our medical device with what are currently the most promising cells. We believe the approach developed by Semma is the most advanced worldwide. Everything points to our collaboration being a great success. So I welcome this partnership, which looks very promising indeed!”
“Defymed offers one of the most promising options available today in terms of a third party immunoprotective device,” said Robert Millman, CEO of Semma Therapeutics. “We’re excited for the collaboration and look forward to the results.”
This exemplary cooperation was recognized as “Best innovative trial design leading to a quicker and better therapeutic outcome” at the MedStartup - Galien Award event on 27 October 2016 in New York.
For Defymed, the collaboration follows just six months after concluding a financial agreement for half a million dollars with the JRDF, a global foundation that funds research into treatment for type-1 diabetes. Defymed also has the support and accompaniment of Business France for its development in the United States. The Strasbourg biotech company is keen to become established in this important market in the very near future.
Defymed, a spin-off of the European centre for the study of diabetes CeeD (Centre Européen d’Étude du Diabète), is a biotechnology company set up in March 2011; it specialises in the design and development of innovative bio-artificial medical devices. Defymed’s initial focus is on developing an application for treating type 1 diabetes. The first product it has designed is MAILPAN©, an implantable bio-artificial pancreas intended to re-establish the normal production of insulin in type 1 diabetics. The MAILPAN© prototype was produced with financial support from the European Commission. The company owns exclusive technology that enables it to produce medical devices for use in other therapeutic applications. Defymed’s strength lies in its network of French and international partners. For more information, please visit www.defymed.com.
About Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients. Work in the laboratory of Professor Douglas Melton led to the discovery of a method to generate billions of functional, insulin-producing beta cells in the laboratory. This breakthrough technology has been exclusively licensed to Semma Therapeutics for the development of a cell-based therapy for diabetes. Ongoing research at Semma Therapeutics is focused on combining these proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. Semma Therapeutics is working to bring new therapeutic options to the clinic and improve the lives of patients with diabetes. The company is headquartered in Cambridge, MA. For more information, visit
COMMUNIQUE DE PRESSE
DEFYMED 8 Avenue Dante 67000 Strasbourg - France Tel. +33 (0)3 90 41 04 46 www.defymed.com
Further information and visuals available on request from our press service:
OXYGEN | Press contacts
2 Rue d’Ingwiller - 67000 Strasbourg [France]
+33 (0)3 67 22 03 25 - firstname.lastname@example.org
+33 (0)6 11 25 48 05 - email@example.com